Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Marco Matucci-Cerinic^#¹, Cosimo Bruni^#², Yannick Allanore³, Massimo Clementi^{4

5}, Lorenzo Dagna^{6

7}, Nemanja S Damjanov⁸, Amato de Paulis⁹, Christopher P Denton¹⁰, Oliver Distler¹¹, David Fox¹², Daniel E Furst^{2

13

14}, Dinesh Khanna¹², Thomas Krieg¹⁵, Masataka Kuwana¹⁶, Eun Bong Lee¹⁷, Mengtao Li¹⁸, Shiv Pillai¹⁹, Yukai Wang²⁰, Xiaofeng Zeng²¹, Gloria Taliani²²

Affiliations

¹ Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.
² Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.
³ Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
⁴ Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.
⁵ Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.
⁶ Vita-Salute San Raffaele University, Milan, Italy.
⁷ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁸ Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.
⁹ Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.
¹⁰ Department of Rheumatology, Royal Free Hospital, University College London, London, UK.
¹¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
¹² Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.
¹³ Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.
¹⁴ University of Washington, Seattle, Washington DC, USA.
¹⁵ Translational Matrix Biology, Medical Faculty, Cologne, Germany.
¹⁶ Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
¹⁷ Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
¹⁸ Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹⁹ Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.
²⁰ Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.
²¹ Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
²² Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy.

^# Contributed equally.

PMID: 32349982
DOI: 10.1136/annrheumdis-2020-217407

Practice Guideline

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Marco Matucci-Cerinic et al. Ann Rheum Dis. 2020 Jun.

. 2020 Jun;79(6):724-726.

doi: 10.1136/annrheumdis-2020-217407. Epub 2020 Apr 29.

Authors

Affiliations

¹ Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy marco.matuccicerinic@unifi.it.
² Department of Experimental and Clinical Medicine, Division of Rheumatology, Università degli Studi di Firenze, Firenze, Toscana, Italy.
³ Rheumatology Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
⁴ Unit of Microbiology and Virology, San Raffaele Hospital, Milano, Lombardia, Italy.
⁵ Unit of Microbiology and Virology, Università Vita Salute San Raffaele, Milano, Lombardia, Italy.
⁶ Vita-Salute San Raffaele University, Milan, Italy.
⁷ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁸ Rheumatology department, University of Belgrade School of Medicine, Belgrade, Serbia.
⁹ Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.
¹⁰ Department of Rheumatology, Royal Free Hospital, University College London, London, UK.
¹¹ Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
¹² Rheumatology department, University of Michigan, Ann Arbor, Michigan, USA.
¹³ Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA.
¹⁴ University of Washington, Seattle, Washington DC, USA.
¹⁵ Translational Matrix Biology, Medical Faculty, Cologne, Germany.
¹⁶ Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
¹⁷ Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
¹⁸ Rheumatology & Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹⁹ Ragon Institute, Massachusetts General Hospital, Cambridge, Massachusetts, USA.
²⁰ Rheumatology department, Shantou Central Hospital, Shantou, Guangdong, China.
²¹ Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
²² Infectious Diseases Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Lazio, Italy.

^# Contributed equally.

PMID: 32349982
DOI: 10.1136/annrheumdis-2020-217407

Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.

Keywords: autoimmune diseases; hydroxychloroquine; scleroderma; systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MMC reports grant and personal fees from Actelion, Biogen, Bayer, Boehringer Ingelheim, CSL Behring, Eli-Lilly, outside the submitted work. CB reports consultancy fee from Actelion, Eli Lilly. YA reports personal fees from Actelion, Bayer, BMS, Boehringer and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi. MC; NSD: none. LD received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. CPD has received consultancy fees and/or research grant funding from Actelion, GlaxoSmithKline, Bayer, Sanofi-Aventis, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, UCB Pharma, Leadiant Biosciences, Corbus, Acceleron. OD had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd, CSL Behring, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). Grants (2 Jahre) from Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma Patent issued: mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). Comment: To investigate potential treatments of scleroderma and its complications. DF has received consulting fees, speaking fees and/or honoraria from Pfizer and research support from Regeneron, Gilead and Seattle Genetics. DEF: Grant/Research Support Corbus, Galapagos GSK, Pfizer, Talaris, CSL Behring, Mitsubishi; Consultant Actelion, Amgen, Corbus, Galapagos, Novartis, Pfizer, Roche/Genentech, Talaris, CSL Behring, Boehringer Ingelheim; DK reports personal fees from Actelion, Abbvie, Bayer, Boehringer-Ingelheim, Chemomab, Corbus, CSL Behring, Genentech/Roche, Gilead, GSK, Mitsubishi Tanabi, Sanofi-Aventis, UCB Pharma. He reports grants from Bayer, Boehringer-Ingelheim, Genentech/Roche, Pfizer, Sanofi-Aventis and has stock options in Eicos Sciences. MK has received consultancy fees and/or research grant funding from Abbvie, Actelion Pharmaceuticals, Astellas, Bayer, Boehringer Ingelheim, Chugai, Corbus, CSL Behring, Eisai, Mochida, Nippon Shinyaku, Novartis, Ono, Pfizer, Reata and Tanabe-Mitsubishi. SP reports SAB from Abpro. TK recieved consultancy fee and grant funding from Actelion.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Affiliations

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous